A novel CAR T-cell therapy has benefitted patients with relapsed acute lymphoblastic leukemia, showing high response rates in ...

Fast Track designation is designed to expedite clinical development and regulatory review timelinesEnrolling patients in the GLEAM trial for ...

To address limitations with CAR T therapies targeting CD19, Allogene Therapeutics Inc. has developed ALLO-329, a ...

Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL) who were treated with the novel ...

FELIX study results reveal obe-cel's potential in relapsed B-cell ALL, achieving 77% remission with low severe toxicity, enhancing CAR T-cell therapy outcomes.

Over the weekend, Bristol Myers Squibb & Co (NYSE:BMY) shared preliminary data from a Phase 1 study of CC-97540 (BMS-986353), ...

▎药明康德内容团队编辑Incyte日前在今年的美国血液学会（ASH）年会的摘要中，公布其CD19靶向单抗Monjuvi（tafasitamab）在关键性3期临床试验inMIND中获得积极结果。分析显示，tafasitamab联合来那度胺（len）和C ...

非霍奇金淋巴瘤（NHL）是一组淋巴造血系统恶性肿瘤的统称，其中以弥漫大B细胞淋巴瘤（DLBCL）最为常见。DLBCL病理类型复杂，临床亚型众多、可表现出不同的预后结局。对化疗敏感的复发/难治性DLBCL患者进行大剂量化疗后自体造血干细胞移植（HD-A ...

Allogene Therapeutics has dropped plans to target one of its allogeneic CAR-Ts at leukemia in the face of competition from ...

The American College of Rheumatology (ACR) 2024 Convergence has just concluded, showcasing significant advancements and ...

产品名称： iFluor 549重组抗小鼠 CD19 单克隆抗体 (克隆号1D3) | 悉得（Syd Labs） PA007374 英文名： iFluor 549 Recombinant Anti-mouse CD19 Monoclonal ...

靶向FRα的索米妥昔单抗注射液是全球唯一一款已上市的铂耐药复发性卵巢癌治疗药物，能够识别肿瘤细胞表面的靶标蛋白，对肿瘤细胞进行精确打击，拥有高效的临床治疗效果。索米妥昔单抗注射液被NCCN指南 ...